Compare Illumina, Inc. (ILMN) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Phillips 66 — how do they compare? Illumina, Inc. trades at $190.82 (market cap $29.12B), while Phillips 66 trades at $223.94 (market cap $89.52B). The key difference: Phillips 66 is far larger — about 3.1× Illumina, Inc.'s market cap, and Phillips 66 pays a 2.26% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | PSX | |
|---|---|---|
Market Cap | $29.12B | $89.52B |
Sector | Health | Energy |
52-Week High | $205.10 | $224.36 |
52-Week Low | $91.00 | $120.04 |
Enterprise Value | $30.48B | $105.99B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $191.79, up 2.04% today, with a neutral technical signal and strong fundamental recovery. The stock shows bullish moving averages but faces resistance near $194. Recent earnings beats and a return to profitability in 2025, with $850M net income, highlight operational turnaround. Revenue remains stable around $4.3B, supported by robust gross margins of 66.38%.
Outlook is positive with analyst consensus Buy rating and $201.58 price target, though high P/E of 35.98 poses valuation risk. Key opportunities include sequencing demand and AI partnerships, while risks involve debt levels and competitive pressures. Institutional activity is mixed, with some funds increasing stakes amid earnings momentum.
Phillips 66 (PSX) trades at $215.52, up 5.69% in the last session, reflecting strong momentum. The stock exhibits bullish technical signals with key support at $208 and resistance at $219. Fundamentally, Q2 2026 EPS of $9.41 significantly beat estimates, driven by robust refining margins and high utilization rates. Recent news highlights the final investment decision for the $5 billion Western Gateway Pipeline joint venture, signaling growth in midstream operations.
Outlook remains positive with analyst consensus favoring Buy ratings (57%) and a $221.92 price target. Key opportunities include sustained refining strength and debt reduction, while risks involve volatile crude prices and geopolitical tensions affecting supply chains. Earnings growth and strategic projects underpin potential upside, but investors should monitor margin pressures and global energy dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
